Advanced glycation and retinal pathology during diabetes.
Of all microvascular complications of diabetes mellitus, retinopathy remains the most common. This disease presents major therapeutic problems for the ophthalmologist and despite many decades of intense research it still constitutes a major cause of blindness in the Western world. This review outlines the pathological characteristics of diabetic retinopathy and proposes a link between disease progression with the formation and accumulation of advanced glycation endproducts (AGEs). AGEs form in vivo from the reaction of glucose and/or alpha-oxaloaldehydes leading to chemical modifications on the amino groups of proteins, lipids and DNA. These heterogenous adducts can modify the structure and function of proteins and lead to intra-molecular and intermolecular cross-link formation. As reported in a range of clinical investigations and determined by mechanistic in vitro and in vivo studies, AGEs accumulate in the diabetic retina where they may be effectors of retinal vascular and neural cell dysfunction. Evidence now points towards a pathogenic role for advanced glycation in the initiation and progression of diabetic retinopathy and this review will examine the current state of knowledge of AGE-related pathology in the retina at a cellular and molecular level. It will also describe how ongoing pharmaceutical strategies to inhibit AGE formation and thereby attenuate their pathogenic influence during chronic hyperglycemia may play a significant role in the treatment of diabetic retinopathy.
Stitt
Alan W
AW
Centre for Vision Science, Queen's University of Belfast, Royal Victoria Hospital, Grosvenor Road, Belfast, BT12 6BA, Northern Ireland, UK. a.stitt@qub.ac.uk
Curtis
Tim M
TM
D000447:Aldehydes / Q000378:metabolism; D000818:Animals; D003930:Diabetic Retinopathy / Q000188:drug therapy / Q000503:physiopathology*; D018450:Disease Progression; D005947:Glucose / Q000378:metabolism; D017127:Glycation End Products, Advanced / Q000037:antagonists & inhibitors / Q000378:metabolism*; D006801:Humans; D006943:Hyperglycemia / Q000150:complications*; D012160:Retina / Q000473:pathology; D012171:Retinal Vessels / Q000503:physiopathology
D000447:Aldehydes; D017127:Glycation End Products, Advanced; D005947:Glucose